Eovist Logo

 

 

 

 

 

Eovist Logo

The Only FDA-Approved Hepatobiliary Specific Contrast Agent (HBA) for MRI Liver Imaging1,2

Eovist® is the only FDA-approved Hepatobiliary Specific Contrast Agent (HBA) for MR liver imaging.1,2 Eovist® is a contrast agent combining dynamic-phase imaging (similar to extracellular agents) along with functional, hepatobiliary phase information to support comprehensive evaluation of focal liver disease1-3,7

Contact a Rep
TS Training Video IBP Callout

Indication

Eovist® (gadoxetate disodium) is indicated for use in magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adult and pediatric patients, including term neonates, with known or suspected focal liver disease.

How Eovist®, a hepatobiliary agent,1 works
  • Following injection, Eovist® is equally eliminated through the renal and hepatic systems
  • Eovist® is initially distributed in the extracellular space, allowing for arterial, portal venous, and transitional imaging phases2,3
  • Further assessment of lesions through hepatobiliary phase imaging at approximately 20 minutes post injection:
    • Lesions with little or no hepatobiliary function will generally not accumulate Eovist®
    • Lesions with normal hepatobiliary function will accumulate Eovist®
IndicationApprovalTimeline_0

 

References: 1. Melanie K. Seale. Hepatobiliary-specific MR Contrast Agents: Role in Imaging the Liver and Biliary Tree. Radiographics.rsna.org; 2009. 2. Eovist [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals; 2018. 3. American College of Radiology CT/MRI Li-RADS 2018 CORE. 4. Zech CJ, Hermann KA, Reiser MF, Shoenberg SO. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent GD-EOB-DTPA. Magn Reson Med Sci. 2007;6:43–52.

Accordion header

    Safety in Clinical Trials

    In clinical trials among 1,989 patients, of whom 1,581 received the recommended dose:

    • Overall, 4% of subjects reported one or more reactions during a follow-up period that for most subjects extended 24 hours after Eovist® administration. The adverse reactions were predominantly of mild to moderate severity.
    • The most frequent (≥0.5%) adverse reactions associated with the use of Eovist® were nausea, headache, feeling hot, dizziness, and back pain.
    Group-93

    Accordion header

      Protocol

      Dynamic and functional liver imaging in <30 minutes1

      Eovist® MRIs don't have to require extended table time.

      Eovist® imaging protocols allow for image acquisition of dynamic+ functional, hepatobiliary information in under 30 minutes, which can be important to your department and patient scheduling needs1-3,*,†

      Gadavsit_Safety_Chart

      †In addition to dynamic-phase imaging, Eovist® specifically targets functioning hepatocytes within the liver, providing additional morphological and functional, hepatobiliary images about lesion cell composition.

      Gadavsit_Safety_Chart

      References: 1. Eovist® [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2018. 2. American College of Radiology CT/MRI Li-RADS 2018 CORE. 3. Jhaveri K, Cleary S, Pascale A. Consensus Statements From a Multidisciplinary Expert Panel on the Utilization and Application of a Liver-Specific MRI Contrast Agent (Gadoxetic Acid). Am J Roentgen AJR. 2015;204:498-509. 4. Yoshioka H, Takahashi N, Yamaguchi M. Double Arterial Phase Dynamic MRI with Sensitivity Encoding (SENSE) for Hypervascular Hepatocellular Carcinomas. J Magn Reson Im. 2002;16:259-266. REF-US-28431. 5. Pietryga JA, Burk LMB, Marin D Respiratory Motion Artifact Affecting Hepatic Arterial Phase imaging with Gadoxetate Disodium. Radiology. 2014;271(2):426-34. REF-US-28430. 6. Manojkumar Saranathan, Dan W. Rettmann. Differential Subsampling with Cartesian (DISCO). J Magn Reson Im 35:1484-1492 (2012). 7. Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics. 2009;29(6):1725-1748. doi:10.1148/rg.296095515

      Accordion header

        Dosing

        Uses less Gadolinium Per Dose Than Extracellular MRI Agents

        chart%402x

        The recommended dose of Eovist® is 0.1mL/kg body weight (0.025 mmol/kg body weight).

        Accordion header

          Case Studies

          See Eovist in action with the case studies below or additional cases linked here. Or go to the Resources section to see all videos.

          For The Detection and Characterization of Focal Liver Disease

          Detecting Focal Liver Lesions:
          MRI with Eovist®

          chart%402x

          Case courtesy of Rajan T. Gupta, M.D., Associate Professor of Radiology, Duke University Medical Center, Duke University, Durham, North Carolina

          The patient data that appears in this document is actual health information but all personal identifiers have been removed or otherwise anonymized. No personally identifiable information is shown.

          chart%402x

          Case courtesy of Dr. Claude Sirlin, University of California San Diego Liver Imaging Group.

           

          Characterizing Lesions with Eovist®

          chart%402x
          chart%402x

          Case courtesy of Dushyant V. Sahani M.D., Director of Computed Tomography, Massachusetts General Hospital and Associate Professor of Radiology. Harvard. Boston, Massachusetts.

          Accordion header

            Ordering Information

            Eovist® Packaging

            • Eovist® injection is supplied in single-dose, rubber-stoppered vials containing 181.43 mg/mL of gadoxetate disodium, equivalent to 0.25 mmol/mL
            • The recommended dose of Eovist® injection is 0.025 mmol/kg body weight
            chart%402x

            For more information on reimbursement and purchasing options, click here. 

            Related Products

            Note: The Bayer in Radiology contrast and device products should be used in accordance with the Prescribing Information and Instructions For Use, respectively.

            Optimize workflows with Contrast Dose Management

            See how

            MEDRAD® MRXperion MR Injection System: A
            Smart Addition

            See product features

            Service and Support You Can Count On

            Browse options

            Related Products

            Note: The Bayer in Radiology contrast and device products should be used in accordance with the Prescribing Information and Instructions For Use, respectively.

            Optimize workflows with Contrast Dose Management

            See how

            MEDRAD®
            MRXperion MR
            Injection System: A
            Smart Addition

            See product features

            Service and Support You Can Count On

            Browse options

              

            INDICATION and IMPORTANT SAFETY INFORMATION

            Read more

            INDICATION

            Eovist® (gadoxetate disodium) is indicated for use in magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adult and pediatric patients, including term neonates, with known or suspected focal liver disease.

            IMPORTANT SAFETY INFORMATION

            WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS

            Risk Associated with Intrathecal Use

            Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. Eovist is not approved for intrathecal use.

            Nephrogenic Systemic Fibrosis 

            GBCAs increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of Eovist in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.

            The risk of NSF appears highest among patients with:

            • Chronic, severe kidney disease (GFR <30 mL/min/1.73m2), or
            • Acute kidney injury

            Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age >60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.

            For patients at highest risk for NSF, do not exceed the recommended Eovist dose and allow a sufficient period of time for elimination of the drug from the body prior to any readministration. .

            Contraindication and Important Information about Hypersensitivity Reactions: Eovist® is contraindicated in patients with history of severe hypersensitivity reactions to Eovist®. Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe, including shock have occurred following Eovist® administration. Before Eovist® administration, assess all patients for any history of a reaction to contrast media, bronchial asthma and allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to Eovist®.

            Gadolinium Retention: Gadolinium is retained for months or years in several organs. Linear GBCAs cause more retention than macrocyclic GBCAs. At equivalent doses, retention varies among the linear agents. Retention is lowest and similar among the macrocyclic GBCAs. Consequences of gadolinium retention in the brain have not been established, but they have been established in the skin and other organs in patients with impaired renal function. While clinical consequences of gadolinium retention have not been established in patients with normal renal function, certain patients might be at higher risk. These include patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions. Consider the retention characteristics of the agent and minimize repetitive GBCA studies, when possible.

            Acute Kidney Injury: In patients with chronic renal impairment, acute kidney injury sometimes requiring dialysis has been observed with the use of GBCAs.Do not exceed the recommended dose; the risk of acute kidney injury may increase with higher than recommended doses. 

            Extravasation and Injection Site Reactions: Extravasation into tissues during Eovist® administration may result in local tissue reactions such as myocyte necrosis and inflammation. Ensure catheter and venous patency before the injection. 

            Interference with Laboratory Tests: Serum iron determination using complexometric methods may result in falsely high or low values for up to 24 hours after the examination with Eovist®.

            Interference with Visualization of Liver Lesions: End stage renal failure or hepatic failure may impair Eovist® imaging performance. In patients with elevated serum ferritin or serum bilirubin >3 mg/dL, reduced hepatic contrast was observed.

            Adverse Reactions: The most frequent (≥0.5%) adverse reactions associated with Eovist® are nausea (1.1%), headache (1.1%), feeling hot (0.8%), dizziness (0.6%), and back pain (0.6%). 

             

            Please see Full Prescribing Information for Eovist®.

            Consulte la información de prescripción completa para Eovist®.

            Medication Guide

            Guía del Medicamento

            Any individuals depicted on this web page are actors and not actual health care providers or patients.
            Patient Information listed on the Graphical User Interfaces are fictitious examples only and do not contain any actual patient data.

            MRI images throughout this website are actual patient cases but all personal identifiers have been removed or otherwise anonymized. No personally identifiable information is shown.

            You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

            © 2020-2026 Bayer

            BAYER, the Bayer Cross, MEDRAD Stellant, MEDRAD Centargo, MEDRAD MRXperion, MEDRAD Stellant FLEX, MEDRAD XDS, MEDRAD Veris, MEDRAD Stellant P3T, MEDRAD Spectris Solaris, MEDRAD Spectris, MEDRAD Mark 7 Arterion, MEDRAD Mark V ProVis, MEDRAD Intego, MEDRAD Avanta, MEDRAD Twist & Go, MEDRAD VFlow, Certegra P3T, MEDRAD FluiDots, MEDRAD Vistron, MEDRAD Envision, MEDRAD Certo, MEDRAD, Stellant, MRXperion, Stellant FLEX, Veris, Spectris Solaris, Spectris, Mark 7 Arterion, Mark V ProVis, Avanta, Envision, Twist & Go, VFlow, Radimetrics, Certegra, P3T, Seamlessly Smart, DirectCARE, PartnerCARE, VirtualCare, SelectCARE and TechCARE are trademarks owned by and/or registered to Bayer in the U.S. and/or other countries.

            Bayer HealthCare LLC 100 Bayer Boulevard, PO Box 915, Whippany, NJ 07981

            Last update:  March 2026

            Bayer-logo-white